Kineret — CareFirst (Caremark)
Chimeric Antigen Receptor (CAR) T-Cell-Related Toxicities
Initial criteria
- For treatment of cytokine release syndrome: Cytokine release syndrome is refractory to high-dose corticosteroids and anti-IL-6 therapy OR Kineret will be used as a replacement for the second dose of tocilizumab when supplies are limited or unavailable.
- For prophylaxis of CAR T-cell-induced toxicity: Member is at high risk of developing high-grade immune effector cell-associated neurotoxicity syndrome (ICANS).
Approval duration
1 month for treatment; 3 months for prophylaxis